Related Experiment Video

Updated: Jul 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

Vincent G Brichard1, Diane Lejeune

  • 1Cancer Immunotherapeutics R&D, GlaxoSmithKline Biologicals, Rue de l'Institut, Rixensart, Belgium. vincent.brichard@gskbio.com

Vaccine
|November 2, 2007
PubMed

Insights

Researchers explored targeting tumor antigens with recombinant proteins and an Adjuvant System. This immunotherapy approach showed promise in non-small cell lung cancer (NSCLC) and may benefit other cancer types.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • The immune system's ability to recognize tumors has led to the identification of various tumor antigens.
  • Multiple strategies targeting these antigens have been investigated in clinical trials.

Purpose of the Study:

  • To evaluate a novel anti-cancer therapy approach using recombinant proteins and an Adjuvant System.
  • To assess the potential of this methodology in treating various tumor types, including non-small cell lung cancer (NSCLC).

Main Methods:

  • Utilizing recombinant proteins combined with a specific immunological Adjuvant System.
  • Applying this methodology within a defined clinical setting.

Main Results:

  • Promising advances were observed with MAGE-A3 immunotherapy in NSCLC.
  • The approach demonstrated potential for developing a well-tolerated anti-cancer therapy.

Conclusions:

  • The recombinant protein and Adjuvant System approach represents a potential new class of anti-cancer therapy.
  • This methodology holds promise for application across diverse tumor types beyond NSCLC.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.